Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma

Ann Hematol. 2023 Apr;102(4):967-969. doi: 10.1007/s00277-023-05120-w. Epub 2023 Feb 8.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Humans
  • Lenalidomide / therapeutic use
  • Multiple Myeloma* / drug therapy

Substances

  • daratumumab
  • Antibodies, Monoclonal
  • Lenalidomide